Vinorelbine-loaded multifunctional magnetic nanoparticles as anticancer drug delivery systems: synthesis, characterization, and in vitro release study

• Zeynep Özcan and
• Afife Binnaz Hazar Yoruç

Beilstein J. Nanotechnol. 2024, 15, 256–269, doi:10.3762/bjnano.15.24

• , magnetic response, and controlled drug release with photothermal effect brings a different perspective to advanced cancer treatment research. Keywords: drug efficacy; iron oxide nanoparticles; photothermal; solvothermal method; Introduction Cancer is a widespread condition characterized by the

Alteration of nanomechanical properties of pancreatic cancer cells through anticancer drug treatment revealed by atomic force microscopy

• Xiaoteng Liang,
• Shuai Liu,
• Xiuchao Wang,
• Dan Xia and
• Qiang Li

Beilstein J. Nanotechnol. 2021, 12, 1372–1379, doi:10.3762/bjnano.12.101

• the physical properties of HeLa cells treated by docetaxel are different from that of untreated ones [9]. Therefore, the study of drug–cell interaction regarding cellular mechanics could be an effective way for drug evaluation. Important information, including drug efficacy and safety can be obtained

Using natural language processing techniques to inform research on nanotechnology

• Nastassja A. Lewinski and
• Bridget T. McInnes

Beilstein J. Nanotechnol. 2015, 6, 1439–1449, doi:10.3762/bjnano.6.149

• parameter was examined. Nanomedicine Through targeted and activatible delivery, nanomedicine has the potential to greatly improve drug efficacy while reducing side effects. Improved design can also address emerging challenges to disease treatment such as adaptive resistance. Despite the promise, few

Anticancer efficacy of a supramolecular complex of a 2-diethylaminoethyl–dextran–MMA graft copolymer and paclitaxel used as an artificial enzyme

• Yasuhiko Onishi,
• Yuki Eshita,
• Rui-Cheng Ji,
• Masayasu Onishi,
• Takashi Kobayashi,
• Masaaki Mizuno,
• Jun Yoshida and
• Naoji Kubota

Beilstein J. Nanotechnol. 2014, 5, 2293–2307, doi:10.3762/bjnano.5.238

• of DDMC/PTX4 (MST: T/C, 2.93) treatment to inhibit melanoma tumor growth was also superior to DDMC/PTX5 (MST: T/C, 2.43) treatment, owing to its small particle size of 50 nm (EPR effect) (p < 0.0033). The in vivo drug efficacy of DDMC/PTX on cancer cells should depend on its EPR effect, avoidance of

• supramolecular anticancer agent. Above all, the supramolecular complex by DDMC/PTX should play an important role as an amplifier of the PTX drug efficacy [64]. Non-viral vectoring of DEAE–dextran and DEAE–dextran–MMA graft copolymer (DDMC). (a) Transfection of DDMC into HEK293 cell lines. The grafting rate is